The purpose of this study was to determine the optimum conditions for labeling genistein compounds with technetium-99m ( 99m Tc) radionuclides and the percentage of purity obtained in accordance with the requirements of the United State Pharmacopeia. The method used is optimization of several parameters including pH, SnCl 2 .2H 2 O as reducing agents, genistein concentration, and incubation time. The results showed that the optimum conditions for labeling 99m Tc-Genistein were obtained under conditions of pH 8, the amount of SnCl 2 .2H 2 O reducing agents was 30 μg, 0.5 mg genistein, and in 10 min. The optimization of this condition resulted in radiochemical purity in the labeling of 99m Tc-Genistein compounds at 95.43% ± 0.85%. The radiochemical purity of the labeling of 99m Tc-Genistein compounds has met the requirements of the United State Pharmacopeia as a compound marked for diagnosis of more than 90%.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.